EFE.- The drug Olaparib reduces by 32% the risk of death in high-risk hereditary early breast cancer with BRCA1 and BRC2 gene mutations.
These are the latest results of the Olympia study presented today by its principal investigator, Andrew Tutt, at a virtual plenary session of the European Society for Medical Oncology (ESMO).
Also read: Inspired by the human ear, they create a tissue that “hears”
These data update those published in June 2021, which already showed a 42% reduction in the risk of relapse in patients with BRCA1 and BRCA2 mutations, the genes involved in the development of hereditary breast cancer.
The results of this second analysis demonstrate both a statistically and clinically significant improvement in overall survival (OS) after one year of olaparib as adjuvant treatment – add-on therapy given after primary treatment – compared to placebo.
We invite you to follow us on Twitter
Specifically, a 32% reduction in the risk of death has been shown in patients with high-risk HER2-negative early breast cancer and BRCA germline mutations.
“Olympia shows that Olaparib reduces the risk of cancer recurrence and increases overall survival in patients with an inherited pathogenic variant in the BRCA1 or BRCA2 genes, which may mark a before and after in the treatment of these patients because they offer the possibility of a cure,” said Dr. Judith Balmaña, who has worked on the study.
These results have already prompted the approval of the drug by the US FDA health authorities last Friday for the target population and in the adjuvant setting, which represents a change in clinical practice.
Download for free the printed edition of Forbes Central America
The treatment was already approved in the metastatic setting and has now been indicated in the early stages of the disease.
The Olympia study involved 1,836 patients with hereditary breast cancer. Eight out of ten participants in this phase III trial specifically suffered from the triple negative subtype, the most frequent in patients with hereditary breast cancer and with fewer treatment options beyond chemotherapy.
We invite you to follow our Facebook page
–
